Analyst Research

Report Title Price
Provider: Stock Traders Daily
Provider: New Constructs, LLC
Provider: Thomson Reuters Stock Report
Provider: ValuEngine, Inc.

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Edwards Lifesciences reaffirms FY 2014 guidance; gives Q2 2014 guidance in line with analysts' estimates

Thursday, 24 Apr 2014 04:03pm EDT 

Edwards Lifesciences Corp:Maintains FY 2014 guidance.Continues to expect FY 2014 total sales of $2.05 billion to $2.25 billion.Says excluding special items, the company expects FY 2014 diluted earnings per share to be in a range around $3.10, which includes an assumed $0.10 benefit from change in the treatment of IP litigation expenses.Projects Q2 2014 total sales to be between $525 million and $565 million.Projects Q2 2014 diluted earnings per share, excluding special items, to be between $0.71 and $0.81.FY 2014 revenue of $2.16 billion and EPS of $3.06 - Thomson Reuters I/B/E/S.Q2 2014 revenue of $543 million and EPS of $0.72 - Thomson Reuters I/B/E/S.